Loading stock data…
AMGN
$322.01-1.84 (-0.57%)
Market OpenUpdated 11:43 AM EDT
Amgen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amgen Inc. in the Healthcare sector is trading at $323.85. The stock is currently 17% below its 52-week high of $391.29, remaining 0.5% above its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why AMGN maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$322.01
Potential Upside
37%
Whystock Fair Value$441.28
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Hold
Mean target$353.43+9.8%
Range$200.00 – $432.00
Fundamentals
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$186.47B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.29
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Strong income play. Yield provides a meaningful total return floor.
292.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
76.45%
Volume
Today's trading volume
674,749
Recent News
Sector Update: Health Care Stocks Softer in Afternoon Trading
Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street H
Amgen invests $300M more in Puerto Rico biologics plant
The additional investment builds on $650 million Amgen committed to its Juncos facility last year, which supplies medicines to more than 60 countries
Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and reflects a model update rather than a wholesale thesis change. Amgen stock recently slipped, trading at $324 as of Monday after closing at ... Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.